Literature DB >> 21806020

The metastasis-promoting phosphatase PRL-3 shows activity toward phosphoinositides.

Victoria McParland1, Giulia Varsano, Xun Li, Janet Thornton, Jancy Baby, Ajay Aravind, Christoph Meyer, Karolina Pavic, Pablo Rios, Maja Köhn.   

Abstract

Phosphatase of regenerating liver 3 (PRL-3) is suggested as a biomarker and therapeutic target in several cancers. It has a well-established causative role in cancer metastasis. However, little is known about its natural substrates, pathways, and biological functions, and only a few protein substrates have been suggested so far. To improve our understanding of the substrate specificity and molecular determinants of PRL-3 activity, the wild-type (WT) protein, two supposedly catalytically inactive mutants D72A and C104S, and the reported hyperactive mutant A111S were tested in vitro for substrate specificity and activity toward phosphopeptides and phosphoinositides (PIPs), their structural stability, and their ability to promote cell migration using stable HEK293 cell lines. We discovered that WT PRL-3 does not dephosphorylate the tested phosphopeptides in vitro. However, as shown by two complementary biochemical assays, PRL-3 is active toward the phosphoinositide PI(4,5)P(2). Our experimental results substantiated by molecular docking studies suggest that PRL-3 is a phosphatidylinositol 5-phosphatase. The C104S variant was shown to be not only catalytically inactive but also structurally destabilized and unable to promote cell migration, whereas WT PRL-3 promotes cell migration. The D72A mutant is structurally stable and does not dephosphorylate the unnatural substrate 3-O-methylfluorescein phosphate (OMFP). However, we observed residual in vitro activity of D72A against PI(4,5)P(2), and in accordance with this, it exhibits the same cellular phenotype as WT PRL-3. Our analysis of the A111S variant shows that the hyperactivity toward the unnatural OMFP substrate is not apparent in dephosphorylation assays with phosphoinositides: the mutant is completely inactive against PIPs. We observed significant structural destabilization of this variant. The cellular phenotype of this mutant equals that of the catalytically inactive C104S mutant. These results provide a possible explanation for the absence of the conserved Ser of the PTP catalytic motif in the PRL family. The correlation of the phosphatase activity toward PI(4,5)P(2) with the observed phenotypes for WT PRL-3 and the mutants suggests a link between the PI(4,5)P(2) dephosphorylation by PRL-3 and its role in cell migration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21806020     DOI: 10.1021/bi201095z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  27 in total

Review 1.  Protein tyrosine phosphatases--from housekeeping enzymes to master regulators of signal transduction.

Authors:  Nicholas K Tonks
Journal:  FEBS J       Date:  2013-01-17       Impact factor: 5.542

2.  Phosphocysteine in the PRL-CNNM pathway mediates magnesium homeostasis.

Authors:  Irina Gulerez; Yosuke Funato; Howie Wu; Meng Yang; Guennadi Kozlov; Hiroaki Miki; Kalle Gehring
Journal:  EMBO Rep       Date:  2016-11-17       Impact factor: 8.807

3.  Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase.

Authors:  John S Lazo; Isabella K Blanco; Nikhil R Tasker; Ettore J Rastelli; James C Burnett; Sharon R Garrott; Duncan J Hart; Rebecca L McCloud; Ku-Lung Hsu; Peter Wipf; Elizabeth R Sharlow
Journal:  J Pharmacol Exp Ther       Date:  2019-10-10       Impact factor: 4.030

Review 4.  Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.

Authors:  Michihiro Kobayashi; Sisi Chen; Rui Gao; Yunpeng Bai; Zhong-Yin Zhang; Yan Liu
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 5.  Phosphatase of regenerating liver: a novel target for cancer therapy.

Authors:  Amanda M Campbell; Zhong-Yin Zhang
Journal:  Expert Opin Ther Targets       Date:  2014-03-01       Impact factor: 6.902

6.  Non-canonical activation of β-catenin by PRL-3 phosphatase in acute myeloid leukemia.

Authors:  Phyllis S Y Chong; Jianbiao Zhou; Jing-Yuan Chooi; Zit-Liang Chan; Sabrina Hui Min Toh; Tuan Zea Tan; Sheena Wee; Jayantha Gunaratne; Qi Zeng; Wee-Joo Chng
Journal:  Oncogene       Date:  2018-10-10       Impact factor: 9.867

7.  A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion.

Authors:  Kelley E McQueeney; Joseph M Salamoun; Jennifer G Ahn; Paula Pekic; Isabella K Blanco; Heather L Struckman; Elizabeth R Sharlow; Peter Wipf; John S Lazo
Journal:  FASEB J       Date:  2018-05-10       Impact factor: 5.191

8.  Discovery of blood transcriptomic markers for depression in animal models and pilot validation in subjects with early-onset major depression.

Authors:  K Pajer; B M Andrus; W Gardner; A Lourie; B Strange; J Campo; J Bridge; K Blizinsky; K Dennis; P Vedell; G A Churchill; E E Redei
Journal:  Transl Psychiatry       Date:  2012-04-17       Impact factor: 6.222

9.  Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion.

Authors:  James J Fiordalisi; Brian J Dewar; Lee M Graves; James P Madigan; Adrienne D Cox
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

10.  Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer.

Authors:  Mark W Zimmerman; Gregg E Homanics; John S Lazo
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.